Skip to main content
Publications
Anthony MS , Djebarri L, Beachler DC, Aroda VR, Calingaert B , Pan C, Crowe C, Lanes S, Rothman KJ , Saltus CW , Berreghis S, Parlett LE, Bocage C, Walsh KE, Juhaeri J, Johannes C . Risk of anaphylaxis among new users of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) . Poster presented at the American Diabetes Association's 83rd Scientific Sessions; June 23, 2023. San Diego, CA. [abstract] Diabetes. 2023 Jun 20; 72(supplement_1):846-P. doi: 10.2337/db23-846-P
Mazurek M, Halperin JL, Huisman MV, Diener HC, Dubner SJ, Ma CS, Rothman KJ , Healey JS, Teutsch C, Paquette M, Franca LR, Lu S, Bartels DB, Lip GYH. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme . Europace. 2020 Jan 1;22(1):47-57. doi: 10.1093/europace/euz278
Huisman MV, Ma CS, Diener HC, Dubner SJ, Halperin JL, Rothman KJ , Teutsch C, Schoof N, Kleine E, Bartels DB, Lip GY. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) phase I cohort . Europace. 2016 Sep;18(9):1308-18. doi: 10.1093/europace/euw073
Herman WH, Hoerger TJ, Hicks K , Brandle M, Sorensen SW, Zhang P, Engelgau MM, Hamman RF, Marrero DG, Ackermann DT, Ratner RE. Managing people at high risk for diabetes . Ann Intern Med. 2006 Jan 3;144(1):66-7.